In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation

Anticancer Res. 2006 Jan-Feb;26(1A):307-10.

Abstract

Background: The study aimed at evaluating the potential benefit from a combination of fractionated ionising radiation with the vascular-targeting compound combretastatin A-4 phosphate (CA-4-P).

Materials and methods: Syngenic rat rhabdomyosarcoma (R1), growing subcutaneously, was treated at 2 different sizes: either small (2 +/- 0.5 cm3) or large (10.94 +/- 0.6 cm3). Localised fractionated irradiation of the tumours (5 x 3 Gy) in 5 days was followed 1 day later by an intraperitoneal CA-4-P treatment (25 mglkg).

Results: The combined treatment of only large tumours resulted in a small additional growth delay when compared with radiotherapy only.

Conclusion: The present data indicate a size-dependent increase in tumour growth delay from combining fractionated irradiation with CA-4-P.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Combined Modality Therapy
  • Dose Fractionation, Radiation
  • Male
  • Rats
  • Rhabdomyosarcoma / drug therapy*
  • Rhabdomyosarcoma / radiotherapy*
  • Stilbenes / pharmacology*

Substances

  • Antineoplastic Agents, Phytogenic
  • Stilbenes
  • fosbretabulin